Vigabatrin (VGB) has been shown through several studies to be safe and effective as add-on therapy, particularly for the treatment of partial seizures in patients with severe epilepsies followed for years in hospital-based clinics. We now report additional clinical experience with VGB arising from an open trial of add-on VGB therapy in patients with relatively few seizures followed by qualified neurologists in private practice (the French Neurologists Sabril@ Study Group). VGB was administered to 397 patients aged 12-74 years (mean age = 37.5 f 13.8 years) who presented with no more than seven partial seizures of any type per month during a 3-month baseline period (mean number of seizures = 3.7 f 1.9/month).
INTRODUCTION
The GABAergic system is thought to play an important role in the origin and spread of epileptic seizures. The therapeutic action of vigabatrin (VGB) is considered to be mediated by the GABAergic system, by irreversible inhibition of GABA-transaminase activity'. Such inhibition results in a 2 to 3-fold elevation of GABA levels in cerebrospinal fluid (CSF), indicating that the drug penetrates into the central nervous system (CNS)'. Clinical experience with VGB (Sabril@) has mainly been gained in Europe, where the first encouraging single-blind studies were published in 1983374 and the drug has been licensed in many countries since 1989.
Although controlled studies are valuable in demonstrating statistically significant efficacy for a given drug, they do not always reflect everyday clinical practice. These classical studies on new antiepileptic drugs (AEDs) are usually carried out in specialist departments for the tertiary referral of AED-resistant patients and often include those for whom surgery has been unsuccessful. Historically, publications on the use of VGB have mainly concerned patients with chronic epilepsy, usually having a substantial number of seizures per month and receiving polytherapy. Most of the patients included in clinical trials were followed in hospital-based clinics or lived in institutions.
In this type of patient, the value of VGB as add-on therapy for the treatment of intractable drug-resistant epilepsies has been showr?.
In both adults and children, the best indication has proved to be epilepsies with partial seizures. Recent studies suggest that VGB may also be especially valuable in the management of infantile spasms'6*17. Experience from more than 10 years of clinical use has demonstrated that VGB has a favourable tolerability protile, being associated with a remarkably low incidence of adverse effects3-18.
The aim of the present study was to explore prospectively the efficacy, tolerability and ease of use of VGB in a patient population that was larger and more representative of patients seen in routine practice than those of previous studies. These patients often have less frequent seizures, are usually out-patients who have not warranted referral to tertiary epilepsy units and are therefore excluded from controlled studies. In a recent study, it was suggested that this type of patient may be even more responsive to VGB than patients with chronic refractory epilepsy.
METHODS
The study population consisted of patients aged between 12 and 74 years, who presented with between one and seven partial seizures of any type per month. Patients with a diagnosis of primary generalized epilepsy (ILAE Classification) were excluded. Participating investigators were all quantified neurologists (French Neurologists Sabril@ Study Group) in private practice.
The 4-month study employed a multicentre, prospective, open design. After an initial 3-month baseline period, patients received VGB as add-on therapy; the initial dose was 2 g/day, given in two doses. The investigator had the authority to introduce the whole dose from day 1 or to introduce it over the course of 1 week. The drug was provided by Marion Merrell Dow as standard vigabatrin 500 mg tablets and was delivered by the investigator. Doses of concomitant anticonvulsant medications were kept constant throughout the study.
Patients were asked to keep a detailed record of seizures during the trial. Follow-up visits were scheduled at weeks 0, 2, 6 and 17. A detailed clinical and neurological examination and an evaluation of weight, arterial pressure and cardiac parameters were carried out at the inclusion visit (week 0) and on week 17. Both clinical evaluations were coupled to an EEG and laboratory tests, including haemoglobin, haematocrit, red and white blood cell count, platelet count, serum glucose, creatinine, uric acid, liver transaminases and gamma-glutamyltransferase.
Patients were instructed to report all adverse reactions that occurred during the study period, regardless of whether they were thought to be associated with VGB. If signs of VGB intolerance occurred, the investigator could reduce the initial 2g/day dose to 1.5 g/day. After 4 weeks of treatment at the recommended 2 g/day regimen, the investigator would increase the dose of VGB progressively, if this was clinically necessary. Investigators were advised to perform the dose adjustment in 0.5 g increments up to a maximum dose of 4g/day. A 7-day interval was to be respected between dose adjustments.
The protocol was approved by an Ethics Committee and each patient provided informed consent before inclusion in the study.
To ensure uniformity of evaluation across all study sites, for both efficacy and tolerability criteria, all investigators were invited to attend one of the 12 study result review meetings that were organized by the study co-ordinator and the study sponsor. In discussing the results with the investigators, our objective was to avoid losing clinical experience with individual patients amongst the total study population.
RESULTS
The demographic characteristics of the 397 patients included are summarized in Table 1 . The mean number of anticonvulsant drugs per patient Analysis of efficacy with respect to seizure type revealed that VGB was particularly effective in patients with secondary generalization (Fig. 1) . Indeed, 84.7% and 78.4% of patients were free from this type of seizure during the first and fourth months of treatment, respectively. Secondary generalization was completely controlled throughout the trial in 55 patients out of 97 (56.7%), of whom 17.5% were free of all types of partial seizures. was 1.9 ( Taking into account the type of patients included in this study, we considered it useful to re-analyse efficacy results in the 369 patients who had received at least 30 days of treatment with VGB. This second analysis permits-evaluation of results in line with clinical practice (Fig. 2) .
During the baseline period, the mean number of seizures per month was 3.7 f 1.9. Simple partial seizures were reported in 121 (30.5%), complex partial seizures in 282 (71.0%) and seizures with secondary generalization in 111 (28.0%).
The mean duration of treatment was 112.4 f 35.3 days. The mean final dose of VGB was 2.21 f 0.64 g/day and 64.2% were maintained on the initial 2 g/day dose.
Efficacy and tolerability were analysed on an intention-to-treat basis. After one month of VGB treatment, 229 patients (57.7%) were free from seizures and during the fourth month, 158 (39.8%) were seizure-free. Reasons for early discontinuation (less than 30 days of treatment) are summarized in Table 3 . A further 69 patients (17.4%) showed a reduction in seizure frequency of more than 50% during the first month of VGB treatment; the corresponding value after 4 months was 17.6%. Overall, therefore, 57.4% of patients showed at least a 50% reduction in Tolerability appeared good, since 206 of the total patients reported no treatment-related adverse events during the study. The remaining 191 reported a wide range of undesirable events. These were assessed as certainly, probably or possibly related to the study drug in 16, 34.5 and 3.7% of cases, respectively. The adverse reactions were assessed as mild in 54.4% of cases, moderate in 32.3% and severe in only 12.3% of cases. No special measure had to be taken in the majority of cases (59.1%). A reduction in VGB dosage was sufficient in 26 patients (6.5% of the total study population) and VGB had to be discontinued in only 32 patients (8%).
The most frequently reported adverse events (Table 4) were sleep disturbances, mainly drowsiness (18% of patients), and irritability (7.1%). There was a trend towards weight gain in 23 patients (5.8%). The mean weight of the patients increased from 67.8 kg (sd = 13.8) to 68.3 (sd = 15.7), but this difference was not statistically significant.
No patient had to discontinue treatment because of an abnormal laboratory value.
The investigators decided to discontinue treatment with VGB in four patients who presented with mild to moderate drowsiness and in another three that complained of rather severe drowsiness. Irritability, together with insomnia, was reported by one patient and another three reported irritability alone. In two patients, VGB was discontinued rather early because of difficulties in concentrating. VGB treatment was interrupted in one patient who presented with an increase in seizure frequency, in two who presented a transitory confusional state, in one who reported visual hallucinations and in one who experienced exacerbation of associated myoclonias. Depression was reported by one patient.
During the investigators' discussions, mood alterations that occurred after the initiation of VGB were reported. These comprised both improvement (which is often associated with improved seizure control) and worsening. In six cases, these were mood disorders likely to be related to VGB treatment. One patient, who was receiving VGB in conjunction with phenobarbital and carbamazepine, attempted suicide. He had experienced a severe road accident, had a previous history of compulsive behaviour episodes and was mentally retarded. VGB was not discontinued but similar episodes were not reported.
DISCUSSION
There are many well-controlled published studies on the efficacy and safety" of VGB. This study was not designed to replicate such trials but to reflect clinical practice and provide neurologists with a realistic expectation when treating patients on an individual basis.
Efficacy
Although one would predict that a drug that demonstrated efficacy and good tolerability when used in refractory epilepsies will also show good efficacy in less severe cases, extrapolation of scientific results is always difficult.
The majority of patients included in this study were socially active people with relatively few seizures per month. Therefore, we attached particular attention to the percentage that remained seizure-free (13.4%) during the whole period following the introduction of VGB. Secondary generalization, a major handicap in socially active patients, was controlled throughout the study in 55 (56.7%) out of 97 patients. It is highly unlikely that such a result is related to a placebo effect.
In most of the controlled studies concerning VGB, the percentage of patients that achieved a more than 50% reduction in seizure frequency was used as a criterion. In the majority of these studies, both in children13,'"*'6 and in adults5-12, more than 40-50% of the patients presented with a reduction in seizure frequency of at least 50%.
The present study clearly demonstrates the efficacy of VGB in paitents with relatively rare partial onset seizures since during the fourth, month of treatment, seizure frequency was reduced by at least 50% in 228 patients (57.4%), 39.8% of whom were seizure-free. If efficacy is assessed on the basis of the 369 patients who received VGB for at least one month (Fig. 2) , seizure frequency at the fourth month was reduced by at least 50% in nearly two-thirds of the patients (62%). These elements complement the results of previous studies on patients with severe epilepsies.
After more than 10 years of clinical use, VGB can now be considered as an important drug in the treatment of partial epilepsies. Effective control of secondary generalization, as demonstrated in the present study, may prove to be an essential characteristic of VGB, especially with the large-scale introduction of the drug into clinical practice.
Clinical adverse events
Only 16% of the adverse events reported during the study were considered by the investigator to be definitely related to VGB and for another 34.5% a probable relation to VGB was proposed. The fact that no special measure was needed in nearly 60% of the cases suggests that these were moderate and transient adverse events. In an additional 9% of cases, a reduction of dose was deemed to be sufficient.
In the authors' experience, the most common problem associated with VGB is drowsiness or sleep disorders. It rarely represents a serious problem, and in the majority of cases tolerance to this side-effect occurs after 1 or 2 weeks of treatment.
As reported by Reynolds, the incidence of drowsiness can be minimized by progressive introduction of VGB". Irritability and poor concentration are occasionally observed, but in our experience discontinuation of the drug is only seldomly required, as these effects usually respond to a reduction in dose. Data from the present study support the opinion that psychotic reactions are rare= with VGB and the few published cases23*24 mainly concerned patients with long-standing epilepsy and a history of severe psychiatric disturbance. Furthermore, the relationship between such phenomena and an abrupt complete control of seizures in patients with long-lasting severe epilepsies represents a complex nosological problem that remains to be elucidated. In patients with a history of severe psychiatric illness, cautious use of VGB is possible, but gradual introduction and an adequate follow-up are necessary.
Exacerbation of seizure frequency may be observed with any AED, but is nevertheless a rare phenomenon.
Some AEDs may have an aggravating effect in certain types of seizure. For example, carbamazepine and vigabatrin may exacerbate myoclonic seizure?. One patient in this study experienced such an effect following introduction of VGB. Although rare, this side-effect should be known as it may be observed in patients suffering from mixed seizure disorders, with several types of seizures. In our experience, these patients may benefit from VGB treatment but should be aware of the risk of exacerbation of myoclonic jerks that can be avoided by using the proper drug combination.
Finally, some patients in this study reported weight gain. According to Tartara et al', an increase of S-16% in initial body weight was observed in 40% of 25 patients over the first 3-6 months of VGB treatment, thereafter tending to reach a plateau. In the present study, some weight gain was reported by 5.8% of the patients, but it was never considered sufficiently lmportant to merit discontinuation of VGB. In the authors' experience, this percentage reflects what is usually observed. In extremely rare cases, pronounced weight gain may justify withdrawal of VGB.
Ease of use
Most of the investigators agreed that VGB was easy to use and stressed that lack of interactions facilitates its use in older patients with symptomatic partial epilepsy, who are likely to be receiving other drugs, especially for cardiovascular disorders.
As VGB is not an enzyme inducer, addition of the drug to previous anti-epilepsy therapy permits a rapid evaluation of its efficacy and eventual side-effects, as no adjustment of the previous treatment is needed. This is often not the case for drugs with a high potential for interaction26J7. Finally, the fact that VGB does not interact with oral contraceptives is important, as few AEDs can be easily used in partial epilepsies for female patients receiving contraception.
Easy titration is another advantage of VGB, compared with drugs for which introduction and adjustment of dose must be longer if one wants to avoid undesirable side-effects and test efficacy. Introduction of a VGB dose of 2 g/day is clinically possible from the first day of treatment. This may prove to be useful in certain circumstances. However, the general principle of progressive introduction of any AED is of value. Data from this study do not suggest that in everyday clinical practice it is necessary to take more than 2 weeks to introduce a VGB dose of 2g/day. Furthermore, due to its mode of action, the general principles of slow withdrawal should be applied.
During the study results review meetings, the fact that follow-up of patients receiving VGB is mainly clinical and that evaluation of blood VGB levels is not necessary engendered some discussions about the usefulness of monitoring AED levels. Such monitoring is undoubtedly a useful tool, especially for certain drugs. However, to respect the patient's quality of life, it should always be remembered that 'therapeutic' and 'toxic' levels can only be regarded individually, on the basis of clinical data. Ranges of 'efficacy' and 'toxicity' for all AEDs are merely statistically established values and should be regarded as such. The mechanism of action of VGB renders a long titration period and determination of plasma drug concentrations unnecessary, thus reducing the overall cost of epilepsy care for a given patient.
From the previous comments it is evident that, irrespective of the personal attitude of the prescriber (immediate vs. rapidly progressive introduction, once or twice daily administration) prescription of a drug that is easy to use, like VGB, reinforces the concept that in the case of well-controlled epilepsy, regular clinical supervision is the only essential measure. CONCLUSIONS 'Having epilepsy is more than just having seizures and every effort should be made to help patients live as normal lives as possible and to support positively their involvement as full members of the community"'. Treatment of epilepsies is always a reasonable compromise between benefits (i.e. control of seizures, improved quality of life) and risks (side-effects, drug interactions, etc.). In terms of efficacy, VGB has already passed successfully the notoriously difficult test of chronic epilepsy patients with severe epilepsies. After ten years of clinical use, adverse events have proved to be infrequent and, for the great majority of patients, transient.
This open, prospective study suggests that VGB is effective and well-tolerated as add-on treatment in the routine management of patients with non-severe partial epilepsy. Control of secondary generalization was achieved in the vast majority of cases. As VGB is easy to use in everyday clinical practice, it has an important role in the early management of patients with uncontrolled partial seizures. Further studies are needed to establish rigorously the possibility of using VGB as a first-line drug for monotherapy.
